复方环丙孕酮与胰岛素增敏剂治疗多囊卵巢综合征的临床治疗效果观察
|
摘要
目的探析多囊卵巢综合征(PCOS)患者应用复方环丙孕酮与胰岛素增敏剂联合治疗的临床效果。方法将本院2015年1月至2017年10月期间接受治疗的120例PCOS患者选为观察对象,依照随机数字表法分为两组,即对照组(n=60)、试验组(n=60)。对照组患者应用复方环丙孕酮治疗,试验组患者在对照组基础上加用胰岛素增敏剂治疗,对两组患者治疗前后糖代谢指标水平、内分泌指标水平及排卵情况进行统计比较。结果试验组患者治疗后空腹血糖(FBG)、稳态模型评估-胰岛β细胞功能指数(Homa-β)、稳态模型评估-胰岛素抵抗指数(Homa-IR)明显低于对照组,对比差异有统计学意义(P<0.05)。试验组患者治疗后睾酮(T)、催乳素(PRL)、黄体生成素(LH)、卵泡刺激素(FSH)水平明显低于对照组,比较差异有统计学意义(P<0.05)。两组患者治疗后排卵率明显升高,相较于治疗前,差异有统计学意义(P<0.05),且试验组明显高于对照组,比较差异有统计学意义(P<0.05)。结论 PCOS患者应用复方环丙孕酮与胰岛素增敏剂联合治疗的临床效果更加确切,不仅可以降低患者糖代谢指标水平与内分泌指标水平,还可以提高患者排卵率,是一种值得临床应用与推广的治疗方案。
Objective To investigate the clinical effect of compound cycloproprogesterone combined with insulin sensitizer in patients with polycystic ovary syndrome(PCOS). Methods 120 patients with PCOS received treatment from January 2015 to October 2017 were divided into two groups: control group(n=60) and experimental group(n=60). The patients in the control group were treated with compound cyproprogesterone, and the patients in the experimental group were treated with insulin sensitizer on the basis of the control group. The levels of glucose metabolism index,endocrine index and ovulation were adjusted before and after treatment in both groups. Results After treatment, fasting blood glucose(FBG),steady-state model(Homa-β), islet β cell function index(Homa-β) and steady-state model evaluation-insulin resistance index(Homa-IR) in the trial group were significantly lower than those in the control group. The difference was statistically significant(P<0.05). The levels of testosterone(T),prolactin(PRL), luteinizing hormone(LH), follicle stimulating hormone(FSH) in the experimental group were significantly lower than those in the control group(P<0. 05). The ovulation rate of the two groups after treatment was significantly higher than that before treatment, the difference was statistically significant. The significance was significant(P<0.05), and the experimental group was significantly higher than the control group, the difference was statistically significant(P<0.05). Conclusion The clinical effect of combined treatment with compound cyclopropofol and insulin sensitizer in PCOS patients is more accurate. It can not only reduce the level of glucose metabolism index and endocrine index, but also increase the ovulation rate of patients. It is a treatment scheme worthy of clinical application and popularization.
Objective To investigate the clinical effect of compound cycloproprogesterone combined with insulin sensitizer in patients with polycystic ovary syndrome(PCOS). Methods 120 patients with PCOS received treatment from January 2015 to October 2017 were divided into two groups: control group(n=60) and experimental group(n=60). The patients in the control group were treated with compound cyproprogesterone, and the patients in the experimental group were treated with insulin sensitizer on the basis of the control group. The levels of glucose metabolism index,endocrine index and ovulation were adjusted before and after treatment in both groups. Results After treatment, fasting blood glucose(FBG),steady-state model(Homa-β), islet β cell function index(Homa-β) and steady-state model evaluation-insulin resistance index(Homa-IR) in the trial group were significantly lower than those in the control group. The difference was statistically significant(P<0.05). The levels of testosterone(T),prolactin(PRL), luteinizing hormone(LH), follicle stimulating hormone(FSH) in the experimental group were significantly lower than those in the control group(P<0. 05). The ovulation rate of the two groups after treatment was significantly higher than that before treatment, the difference was statistically significant. The significance was significant(P<0.05), and the experimental group was significantly higher than the control group, the difference was statistically significant(P<0.05). Conclusion The clinical effect of combined treatment with compound cyclopropofol and insulin sensitizer in PCOS patients is more accurate. It can not only reduce the level of glucose metabolism index and endocrine index, but also increase the ovulation rate of patients. It is a treatment scheme worthy of clinical application and popularization.
引文
[1]梁法亮,谭文锵,梁宝珠,等.二甲双胍联合氯米芬对胰岛素抵抗的多囊卵巢综合征促排卵疗效观察[J].北方药学,2018,15(1):59.
[2]魏颖.复方醋酸环丙孕酮与二甲双胍干预对改善多囊卵巢综合征内分泌的影响分析[J].实用妇科内分泌杂志,2016,3(7):20-22.
[3]杨红燕.胰岛素增敏剂对多囊卵巢综合征内分泌紊乱患者的疗效观察[J].实用妇科内分泌杂志,2017,4(16):46-48.
[4]丁立娟.胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱患者的效果观察[J].实用妇科内分泌杂志,2017,4(15):59-60.
[5]宋云焕,申太峰,陈贵芹.复方醋酸环丙孕酮与二甲双胍干预对改善多囊卵巢综合征内分泌的影响[J].河南医学研究,2017,26(3):430-431.
[6]王赵伟.避孕药物联合胰岛素增敏剂治疗多囊卵巢综合征的临床疗效观察[J].临床合理用药杂志,2017,10(3):59-60.
[7]苏雅琴,宋玉霞.复方环丙孕酮与胰岛素增敏剂治疗多囊卵巢综合征的临床研究[J].世界最新医学信息文摘,2016,16(A5):121-128.
[8]陈贤,罗滢.胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱患者的效果观察[J].中国生化药物杂志,2016,36(11):109-111.
[9]张丽波.复方环丙孕酮与胰岛素增敏剂对多囊卵巢综合征治疗的疗效分析[J].实用妇科内分泌杂志,2017,4(26):23-24.
[10]胡德龙,朱詹雯.胰岛素增敏剂对多囊卵巢综合征内分泌紊乱患者的疗效观察[J].临床医学,2016,36(6):103-104.
[11]苏琳.多囊卵巢综合征不孕患者实施综合护理干预对其生存质量及抑郁的临床影响研究[J].当代医学,2018,24(27):181-182.
[12]丁娇,邵军晖,简皓,等.抗苗勒氏管激素(AMH)与多囊卵巢综合征相关性的临床研究[J].当代医学,2018,24(28):93-95.
[13]美荣,陈必良.多囊卵巢综合征患者HB-EGF、p-JNK、CHOP水平及其临床意义分析[J].临床和实验医学杂志,2018,17(20):2183-2186.
[14]高蓓,王志新.抗雄激素治疗后多囊卵巢综合征患者的产科结局[J].当代医学,2018,24(26):115-117.
[15]王萍.二甲双胍联合达英-35治疗多囊卵巢综合征的临床疗效研究[J].中国现代药物应用,2018,12(19):126-127.
[2]魏颖.复方醋酸环丙孕酮与二甲双胍干预对改善多囊卵巢综合征内分泌的影响分析[J].实用妇科内分泌杂志,2016,3(7):20-22.
[3]杨红燕.胰岛素增敏剂对多囊卵巢综合征内分泌紊乱患者的疗效观察[J].实用妇科内分泌杂志,2017,4(16):46-48.
[4]丁立娟.胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱患者的效果观察[J].实用妇科内分泌杂志,2017,4(15):59-60.
[5]宋云焕,申太峰,陈贵芹.复方醋酸环丙孕酮与二甲双胍干预对改善多囊卵巢综合征内分泌的影响[J].河南医学研究,2017,26(3):430-431.
[6]王赵伟.避孕药物联合胰岛素增敏剂治疗多囊卵巢综合征的临床疗效观察[J].临床合理用药杂志,2017,10(3):59-60.
[7]苏雅琴,宋玉霞.复方环丙孕酮与胰岛素增敏剂治疗多囊卵巢综合征的临床研究[J].世界最新医学信息文摘,2016,16(A5):121-128.
[8]陈贤,罗滢.胰岛素增敏剂治疗多囊卵巢综合征内分泌紊乱患者的效果观察[J].中国生化药物杂志,2016,36(11):109-111.
[9]张丽波.复方环丙孕酮与胰岛素增敏剂对多囊卵巢综合征治疗的疗效分析[J].实用妇科内分泌杂志,2017,4(26):23-24.
[10]胡德龙,朱詹雯.胰岛素增敏剂对多囊卵巢综合征内分泌紊乱患者的疗效观察[J].临床医学,2016,36(6):103-104.
[11]苏琳.多囊卵巢综合征不孕患者实施综合护理干预对其生存质量及抑郁的临床影响研究[J].当代医学,2018,24(27):181-182.
[12]丁娇,邵军晖,简皓,等.抗苗勒氏管激素(AMH)与多囊卵巢综合征相关性的临床研究[J].当代医学,2018,24(28):93-95.
[13]美荣,陈必良.多囊卵巢综合征患者HB-EGF、p-JNK、CHOP水平及其临床意义分析[J].临床和实验医学杂志,2018,17(20):2183-2186.
[14]高蓓,王志新.抗雄激素治疗后多囊卵巢综合征患者的产科结局[J].当代医学,2018,24(26):115-117.
[15]王萍.二甲双胍联合达英-35治疗多囊卵巢综合征的临床疗效研究[J].中国现代药物应用,2018,12(19):126-127.